Brayton Purcell LLP

Call For A Free Consultation
800-598-0314

Call For A Free Consultation 800-598-0314

Brayton Purcell LLP
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Contact
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Contact

Drug trials attack mesothelioma

On behalf of Brayton Purcell LLP | May 6, 2014 | Mesothelioma

Mesothelioma is a brutal, relentless disease. Like some frightening predator from a gothic novel, it lies in wait, sometimes for ten or twenty years, other times for nearly half a century, only to awaken long after the victim has forgotten that dust they inhaled decades ago, and strike with a cough that turns deadly, often giving the victim little more than a year’s time before it finishes them off.

Hope is the one thing mesothelioma patients need most. And, of course, the drugs or treatment than can provide that hope. As one of the rare victims who survived their initial attack of the disease notes, they have a 4 percent survival rate. In the U.S., 3,000 people fall victim to the disease every year, worldwide the death toll is more than 100,000.

These numbers are likely to grow, especially worldwide, as asbestos has remained in widespread use in many places throughout the world, even after its use was restricted or banned.

Today, as the head of one of the ongoing drug trials put it, “This is not a curable cancer.” Numerous drug trials are currently working on ways of changing that and giving mesothelioma patients a better chance at long-term survival.

One survivor does not fit the stereotype of an old shipyard worker; she was a 36-year-old woman. She apparently was exposed to the deadly asbestos fibers on her father’s work clothes.

She would hug him as a little girl when he came home from his demolition work. His clothing was probably contaminated with untold millions of the deadly asbestos fibers, and in her excitement to see her father, she may have inhaled deep breaths full of the invisible, but fatal, fibers.

With millions of tons of asbestos embedded in the very floors, walls and ceilings of buildings throughout the world, we can only hope that these drug trials will transform mesothelioma into a treatable disease.

Recent Posts

  • Boiler Room Workers and Asbestos Exposure
  • Mitigating the financial impact of mesothelioma treatments
  • The EPA’s difficulty with data disclosure
  • Judge orders EPA to close loopholes on asbestos-related reporting
  • Department of Veterans Affairs Increases Pension Rate for 2021

Archives

Categories

RSS Feed

Subscribe To This Blog’s Feed

Free Consultation

Take The First Step In Resolving Your Issue. Send Us An Email.

Email Us For A Response

San Francisco
Bay Area Office

222 Rush Landing Road Novato, CA 94945

Novato Office
222 Rush Landing Road
Novato, CA 94945
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions

Southern California
Office

12 28th Street Venice, California 90291

Los Angeles Office
12 28th Street
Venice, California 90291
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2021 Brayton Purcell LLP. All Rights Reserved.

Disclaimer | Site Map | Privacy Policy | Business Development Solutions by FindLaw, part of Thomson Reuters

Review Us